

Marina Macchini

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/188835/publications.pdf>

Version: 2024-02-01

27
papers

1,398
citations

686830

13
h-index

525886

27
g-index

29
all docs

29
docs citations

29
times ranked

2178
citing authors

#	ARTICLE	IF	CITATIONS
1	The impact of nutritional status on pancreatic cancer therapy. <i>Expert Review of Anticancer Therapy</i> , 2022, 22, 155-167.	1.1	8
2	Evolving pancreatic cancer treatment: From diagnosis to healthcare management. <i>Critical Reviews in Oncology/Hematology</i> , 2022, 169, 103571.	2.0	17
3	Epidemiology and geographic distribution of BRCA1-2 and DNA Damage response genes pathogenic variants in pancreatic ductal adenocarcinoma patients. <i>Cancer Treatment Reviews</i> , 2022, 104, 102357.	3.4	4
4	Exploring chemotherapy holiday and drugs re-challenge in advanced pancreatic cancer patients. <i>Cancer Chemotherapy and Pharmacology</i> , 2021, 87, 95-101.	1.1	3
5	Multidrug regimens for treatment of older patients with metastatic pancreatic cancer. <i>Digestive and Liver Disease</i> , 2021, 53, 117-121.	0.4	1
6	Germinal BRCA1-2 pathogenic variants (gBRCA1-2pv) and pancreatic cancer: epidemiology of an Italian patient cohort. <i>ESMO Open</i> , 2021, 6, 100032.	2.0	19
7	Chemotherapy toxicity and activity in patients with pancreatic ductal adenocarcinoma and germline BRCA1-2 pathogenic variants (gBRCA1-2pv): a multicenter survey. <i>ESMO Open</i> , 2021, 6, 100238.	2.0	12
8	Treatment opportunities and future perspectives for pancreatic cancer patients with germline BRCA1-2 pathogenic variants. <i>Cancer Treatment Reviews</i> , 2021, 100, 102262.	3.4	16
9	CTNI-51. ADJUVANT TROTABRESIB, A REVERSIBLE POTENT BROMODOMAIN AND EXTRATERMINAL INHIBITOR, PLUS TEMOZOLOMIDE IN PATIENTS WITH NEWLY DIAGNOSED GLIOBLASTOMA: INTERIM RESULTS FROM A PHASE 1B DOSE-FINDING STUDY. <i>Neuro-Oncology</i> , 2021, 23, vi71-vi72.	0.6	0
10	Circulating Chromogranin A Is Cleaved Into Vasoregulatory Fragments in Patients With Pancreatic Ductal Adenocarcinoma. <i>Frontiers in Oncology</i> , 2020, 10, 613582.	1.3	2
11	Interleukin-1 β -induced pancreatitis promotes pancreatic ductal adenocarcinoma via B lymphocyte-mediated immune suppression. <i>Gut</i> , 2020, 70, gutjnl-2019-319912.	6.1	32
12	Time to CA19-9 nadir: a clue for defining optimal treatment duration in patients with resectable pancreatic ductal adenocarcinoma. <i>Cancer Chemotherapy and Pharmacology</i> , 2020, 85, 641-650.	1.1	8
13	Chemotherapy in elderly patients with pancreatic cancer: Efficacy, feasibility and future perspectives. <i>Cancer Treatment Reviews</i> , 2019, 72, 1-6.	3.4	46
14	β 2 Adrenergic-Neurotrophin Feedforward Loop Promotes Pancreatic Cancer. <i>Cancer Cell</i> , 2018, 33, 75-90.e7.	7.7	287
15	Cholinergic Signaling via Muscarinic Receptors Directly and Indirectly Suppresses Pancreatic Tumorigenesis and Cancer Stemness. <i>Cancer Discovery</i> , 2018, 8, 1458-1473.	7.7	158
16	Nab-paclitaxel plus gemcitabine with or without capecitabine and cisplatin in metastatic pancreatic adenocarcinoma (PACT-19): a randomised phase 2 trial. <i>The Lancet Gastroenterology and Hepatology</i> , 2018, 3, 691-697.	3.7	50
17	A randomised phase 2 trial of nab-paclitaxel plus gemcitabine with or without capecitabine and cisplatin in locally advanced or borderline resectable pancreatic adenocarcinoma. <i>European Journal of Cancer</i> , 2018, 102, 95-102.	1.3	50
18	Nerve Growth Factor Promotes Gastric Tumorigenesis through Aberrant Cholinergic Signaling. <i>Cancer Cell</i> , 2017, 31, 21-34.	7.7	332

#	ARTICLE	IF	CITATIONS
19	Retroperitoneal lymphangioma: A report of 2 cases and a review of the literature regarding the differential diagnoses of retroperitoneal cystic masses. <i>Oncology Letters</i> , 2016, 11, 3161-3166.	0.8	17
20	Dclk1 Defines Quiescent Pancreatic Progenitors that Promote Injury-Induced Regeneration and Tumorigenesis. <i>Cell Stem Cell</i> , 2016, 18, 441-455.	5.2	196
21	State of the art biological therapies in pancreatic cancer. <i>World Journal of Gastrointestinal Oncology</i> , 2016, 8, 55.	0.8	30
22	Characterization of pancreatic ductal adenocarcinoma using whole transcriptome sequencing and copy number analysis by single-nucleotide polymorphism array. <i>Molecular Medicine Reports</i> , 2015, 12, 7479-7484.	1.1	20
23	Antiprotease Strategy in Pancreatic Cancer Treatment. <i>Pancreas</i> , 2014, 43, 53-63.	0.5	3
24	Preoperative Gemcitabine and Oxaliplatin in a Patient with Ovarian Metastasis from Pancreatic Cystadenocarcinoma. <i>Case Reports in Gastroenterology</i> , 2012, 6, 530-537.	0.3	11
25	Hedgehog signaling: From the cuirass to the heart of pancreatic cancer. <i>Pancreatology</i> , 2012, 12, 388-393.	0.5	9
26	Chemotherapy followed by chemoradiotherapy in locally advanced pancreatic cancer: A literature review and report of two cases. <i>Oncology Letters</i> , 2011, 2, 195-200.	0.8	1
27	Venous Thromboembolism and Port-Related Thrombosis in Metastatic Colorectal Cancer Patients: A Monocenter Experience. <i>Pathophysiology of Haemostasis and Thrombosis: International Journal on Haemostasis and Thrombosis Research</i> , 2010, 37, 30-34.	0.5	6